



Aug 25, 2020

Schedule of Study Visits and Evaluations (Appendix A of Phase 3 study of Vaccine Candidate for COVID-19)

In 1 collection

Chris Ockenhouse¹, Chris Gast¹, Renee Holt¹, Jorge Flores¹¹Center for Vaccine Innovation and Access, PATH (Washington D.C. and Seattle, Washington)

1 Works for me dx.doi.org/10.17504/protocols.io.bj6bkran

Coronavirus Method Development Community PATH

Chris Ockenhouse

ABSTRACT

This is Appendix A of "Phase 3 randomized, double-blinded, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of **Vaccine Candidate** against COVID-19 in adults > 18 years of age"

This generic Phase 3 protocol was developed by the PATH team with support of the Bill and Melinda Gates Foundation. The aim of the collection is to share recommended best practices in designing and implementing a Phase 3 study of a COVID-19 vaccine candidate. As Phase 3 trials of different Vaccine Candidates proceed around the world, following the same protocols will ensure consistency and comparability of the Phase 3 trial results.

Please note that this is an evolving document, to be versioned and updated, based on community feedback and new data.

ATTACHMENTS

Generic Phase 3 Protocol
COVID-19 Vaccine-
25AUG2020-version
1.docx

DOI

dx.doi.org/10.17504/protocols.io.bj6bkran

PROTOCOL CITATION

Chris Ockenhouse, Chris Gast, Renee Holt, Jorge Flores 2020. Schedule of Study Visits and Evaluations (Appendix A of Phase 3 study of Vaccine Candidate for COVID-19). **protocols.io**
<https://dx.doi.org/10.17504/protocols.io.bj6bkran>

COLLECTIONS ⓘ

PATH **Collection of Protocols and Guidelines for Phase 3 study of Vaccine Candidate for COVID-19**

LICENSE

————— This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

Aug 22, 2020

LAST MODIFIED

Aug 25, 2020

OWNERSHIP HISTORY

Aug 22, 2020  Lenny Teytelman protocols.io

Aug 25, 2020  Chris Ockenhouse

PROTOCOL INTEGER ID

40867

PARENT PROTOCOLS

Part of collection

[Collection of Protocols and Guidelines for Phase 3 study of Vaccine Candidate for COVID-19](#)

GUIDELINES

APPENDIX A: SCHEDULE OF STUDY VISITS AND EVALUATIONS -EXAMPLE PROVIDED; VACCINE DEPENDENT

Study Day	-7 to 1	1	15 (+7 days)	29 (+5 days)	57 (+5 days)	57 to study end	180	365/ 730
Visit #	1	2	3	4	5	6	7	8
Clinic visits	X	X	X	X	X		X	X
Phone call, SMS text, email (approximately every two weeks)						X		
Informed consent form signed	X							
Initial screening	X							
Inclusion and exclusion criteria	X	X	X					
Demographic data	X							
Medical history screening	X							
Height/weight measurements	X							
Vital signs/physical examination screening	X							
Blood collection for safety: hematology (CBC), ALT, AST, Bilirubin, creatinine	X							
Nasopharyngeal swab for SARS-CoV-2 RT-PCR		X						
Blood collection for serology (X mL)		X	X	X			X	X
Randomization		X						
Concomitant medication	X	X	X	X	X	X		
Pregnancy test (urine or blood)	X	X	X					
Study vaccination		X	X					
Interim medical history		X	X	X	X			X
Review of diary/memory aid			X	X	X			
Vital signs/targeted physical examination		X	X					
COVID-19 case capture		X	X	X	X	X	X	X
Total blood volume (mL)	X	X	X	X	X		X	X
Study end								X